Sandoz loses copycat case concerning blockbuster drug
Sandoz has violated the marketing authorization for a Biogen drug, according to the court. Injunctions are coming, but according to the CEO, the case is based on ”a series of misunderstandings.”
Illegal trade in sclerosis medication containing dimethyl fumarate has now resulted in both a ban and a recall order for Sandoz. from the Danish Maritime and Commercial Court.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
